ADVATE

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
ADVATE
Generic name
ANTIHEMOPHILIC FACTOR (RECOMBINANT)
Manufacturer
Takeda Pharmaceuticals America, Inc.
Product type
PLASMA DERIVATIVE
SPL set ID
80fa03d2-cd4c-4155-9b57-1396c4fa42da
SPL ID
13243ff1-40ce-41c2-964d-279a9ec57595
Version
13
Effective date
2025-04-03
Source export date
2026-11-13
Source partition
10
Source file
https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/829e43b83940afb8dda22d5287c5b17e57d3fe45d1157678854b4f9b7ad07271/drug-label-0010-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 17:15:32

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions, including anaphylaxis, may occur. Patients may develop hypersensitivity to mouse or hamster protein, which is present in trace amounts in the product. Should symptoms occur, discontinue treatment with ADVATE and administer appropriate treatment. ( 5.1 ) Development of activity-neutralizing antibodies may occur. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration. ( 5.2 , 5.3 ) 5.1 Hypersensitivity Reactions Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with ADVATE. Symptoms include dizziness, paresthesia, rash, flushing, facial swelling, urticaria, dyspnea, pruritus, and vomiting. ADVATE contains trace amounts of mouse immunoglobulin G (MuIgG) ≤0.1 ng/IU ADVATE, and hamster proteins ≤1.5 ng/IU ADVATE. Patients treated with this product may develop hypersensitivity to these nonhuman mammalian proteins. Discontinue ADVATE if hypersensitivity symptoms occur and administer appropriate emergency treatment. 5.2 Neutralizing Antibodies Neutralizing antibodies (inhibitors) have been reported following administration of ADVATE predominantly in previously untreated patients (PUPs) and previously minimally treated patients (MTPs). Monitor all patients for the development of factor VIII inhibitors by appropriate clinical observation and laboratory testing. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor VIII inhibitor concentration [see Warnings and Precautions (5.3) ] . 5.3 Monitoring Laboratory Tests Monitor plasma factor VIII activity levels by the one-stage clotting assay to confirm the adequate factor VIII levels have been achieved and maintained when clinically indicated [see Dosage and Administration (2.1) ] . Monitor for development of factor VIII inhibitors. Perform the Bethesda assay to determine if factor VIII inhibitor is present. If expected factor VIII activity plasma levels are not attained, or if bleeding is not controlled with the expected dose of ADVATE, use Bethesda Units (BU) to titer inhibitors. If the inhibitor titer is less than 10 BU per mL, the administration of additional antihemophilic factor concentrate may neutralize the inhibitor and may permit an appropriate hemostatic response. If the inhibitor titer is above 10 BU per mL, adequate hemostasis may not be achieved. The inhibitor titer may rise following ADVATE infusion as a result of an anamnestic response to factor VIII. The treatment or prevention of bleeding in such patients requires the use of alternative therapeutic approaches and agents.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 3 matching rows.

adverse reactions

6 ADVERSE REACTIONS Serious adverse reactions seen with ADVATE are hypersensitivity reactions, including anaphylaxis, and the development of high-titer inhibitors necessitating alternative treatments to factor VIII. The most common adverse reactions observed in clinical trials (frequency greater than 5% of subjects) were pyrexia, headache, cough, nasopharyngitis, arthralgia, vomiting, upper respiratory tract infection, limb injury, nasal congestion, and diarrhea. Serious adverse drug reactions reported are hypersensitivity and factor VIII inhibitors. ( 6.1 ) The most common adverse drug reactions observed in greater than 5% of patients are pyrexia, headache, cough, nasopharyngitis, arthralgia, vomiting, upper respiratory tract infection, limb injury, nasal congestion, and diarrhea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice. ADVATE has been evaluated in 11 clinical trials in previously treated patients (PTPs) and one trial in previously untreated patients (PUPs) with severe to moderately severe hemophilia A (factor VIII ≤2% of normal). A total of 418 subjects have been treated with ADVATE as of January 2012. Total exposure to ADVATE was 63,188 infusions. The median duration of participation per subject was 397 (min-max: 2−1620) days and the median number of exposure days to ADVATE per subject was 97 (min-max: 1−709). The summary of adverse reactions with a frequency >5% are shown in Table 3 below. No subject was withdrawn from a clinical trial due to an adverse reaction. Table 3: Summary of Adverse Reactions (ARs) Adverse reactions are defined as all adverse events that occurred (a) within 24 hours after being infused with investigational product, or (b) all adverse events assessed related or possibly related to investigational product, or (c) adverse events for which the investigator's or sponsor's opinion of causality was missing or indeterminate. with a Frequency Greater than 5% in 418 The ADVATE clinical program included 418 treated subjects from 11 completed studies in PTPs and 1 completed trial in PUPs. Subjects MedDRA MedDRA version 8.1 was used. System Organ Class MedDRA Preferred Term Number of Adverse Reactions Number of Subjects Percent of Subjects General Disorders and Administration Site Conditions Pyrexia 110 66 16 Nervous System Disorders Headache 114 56 13 Respiratory, Thoracic and Mediastinal Disorders Cough 86 54 13 Infections and Infestations Nasopharyngitis 72 49 12 Musculoskeletal and Connective Tissue Disorders Arthralgia 49 32 8 Gastrointestinal Disorders Vomiting 41 31 7 Infections and Infestations Upper Respiratory Tract Infection 35 29 7 Injury, Poisoning and Procedural Complications Limb Injury 56 25 6 Respiratory, Thoracic and Mediastinal Disorders Nasal Congestion 32 25 6 Gastrointestinal Disorders Diarrhea 29 24 6 Injury, Poisoning and Procedural Complications Procedural Pain 26 22 5 Respiratory, Thoracic and Mediastinal Disorders Oropharyngeal Pain 25 22 5 Infections and Infestations Ear Infection 30 21 5 Immunogenicity The development of factor VIII inhibitors with the use of ADVATE was evaluated in clinical trials with pediatric PTPs (<6 years of age with ≥50 factor VIII exposures) and PTPs (≥10 years of age with ≥150 factor VIII exposures). Of 276 subjects who were treated with ADVATE for at least 10 exposure days or on study for a minimum of 120 days, 1 adult developed a low-titer inhibitor (2 BU in the Bethesda assay) after 26 exposure days. Eight weeks later, the inhibitor was no longer detectable, and in vivo recovery was normal at 1 and 3 hours after infusion of another marketed recombinant factor VIII concentrate. This event results in a factor VIII inhibitor frequency in PTPs of 0.4% (95% CI of 0.01 and 2% for the risk of any factor VIII inhibitor development). 3 No factor VIII inhibitors were detected in the 53 treated pediatric PTPs. In clinical trials that enrolled previously untreated subjects (defined as having had up to 3 exposures to a factor VIII product at the time of enrollment), 16 (29.1%) of 55 subjects who received ADVATE developed inhibitors to factor VIII. Seven subjects developed high-titer (>5 BU) and nine subjects developed low-titer inhibitors. Inhibitors were detected at a median of 13 exposure days (min-max: 6 to 26 exposure days) to the product. Immunogenicity also was evaluated by measuring the development of antibodies to heterologous proteins. When assessed for anti-Chinese hamster ovary (CHO) cell protein antibodies, of 229 treated subjects, 3 showed an upward trend in antibody titer over time and 10 showed repeated but transient elevations of antibodies. When assessed for muIgG protein antibodies, of the 229 treated subjects, 10 showed an upward trend in anti-muIgG antibody titer over time and 2 showed repeated but transient elevations of antibodies. Four subjects who demonstrated antibody elevations to CHO cell or muIgG proteins, reported isolated events of urticaria, pruritus, rash, and slightly elevated eosinophil counts. All of these subjects had numerous repeat exposures to the product without recurrence of the events and a causal relationship between the antibody findings and these clinical events has not been established. When assessed for the presence of anti-human von Willebrand Factor (VWF) antibodies, of the 228 treated subjects, none displayed laboratory evidence indicative of a positive serologic response. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to ADVATE with the incidence of antibodies to other products may be misleading. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of ADVATE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Table 4 represents the most frequently reported postmarketing adverse reactions as MedDRA Preferred Terms. Table 4: Postmarketing Experience Organ System [MedDRA Primary SOC] Preferred Term Immune System Disorders Anaphylactic reaction Hypersensitivity General Disorders and Administration Site Conditions Injection site reaction Chills Fatigue/Malaise Chest discomfort/pain Decreased therapeutic effect

adverse reactions table

<table width="75%"><caption>Table 3: Summary of Adverse Reactions (ARs)<footnote>Adverse reactions are defined as all adverse events that occurred (a) within 24 hours after being infused with investigational product, or (b) all adverse events assessed related or possibly related to investigational product, or (c) adverse events for which the investigator&apos;s or sponsor&apos;s opinion of causality was missing or indeterminate.</footnote> with a Frequency Greater than 5% in 418<footnote>The ADVATE clinical program included 418 treated subjects from 11 completed studies in PTPs and 1 completed trial in PUPs.</footnote> Subjects</caption><col width="30%" align="left" valign="middle"/><col width="20%" align="left" valign="middle"/><col width="17%" align="center" valign="middle"/><col width="17%" align="center" valign="middle"/><col width="16%" align="center" valign="middle"/><thead><tr><th styleCode="Lrule Rrule" align="center">MedDRA<footnote>MedDRA version 8.1 was used.</footnote> System Organ Class</th><th styleCode="Rrule" align="center">MedDRA Preferred Term</th><th styleCode="Rrule">Number of Adverse Reactions</th><th styleCode="Rrule">Number of Subjects</th><th styleCode="Rrule">Percent of Subjects</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule">General Disorders and Administration Site Conditions</td><td styleCode="Rrule">Pyrexia</td><td styleCode="Rrule">110</td><td styleCode="Rrule">66</td><td styleCode="Rrule">16</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Nervous System Disorders</td><td styleCode="Rrule">Headache</td><td styleCode="Rrule">114</td><td styleCode="Rrule">56</td><td styleCode="Rrule">13</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Respiratory, Thoracic and Mediastinal Disorders</td><td styleCode="Rrule">Cough</td><td styleCode="Rrule">86</td><td styleCode="Rrule">54</td><td styleCode="Rrule">13</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Infections and Infestations</td><td styleCode="Rrule">Nasopharyngitis</td><td styleCode="Rrule">72</td><td styleCode="Rrule">49</td><td styleCode="Rrule">12</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Musculoskeletal and Connective Tissue Disorders</td><td styleCode="Rrule">Arthralgia</td><td styleCode="Rrule">49</td><td styleCode="Rrule">32</td><td styleCode="Rrule">8</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Gastrointestinal Disorders</td><td styleCode="Rrule">Vomiting</td><td styleCode="Rrule">41</td><td styleCode="Rrule">31</td><td styleCode="Rrule">7</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">Infections and Infestations</td><td styleCode="Rrule">Upper Respiratory Tract Infection</td><td styleCode="Rrule">35</td><td styleCode="Rrule">29</td><td styleCode="Rrule">7</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Injury, Poisoning and Procedural Complications</td><td styleCode="Rrule">Limb Injury</td><td styleCode="Rrule">56</td><td styleCode="Rrule">25</td><td styleCode="Rrule">6</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Respiratory, Thoracic and Mediastinal Disorders</td><td styleCode="Rrule">Nasal Congestion</td><td styleCode="Rrule">32</td><td styleCode="Rrule">25</td><td styleCode="Rrule">6</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Gastrointestinal Disorders</td><td styleCode="Rrule">Diarrhea</td><td styleCode="Rrule">29</td><td styleCode="Rrule">24</td><td styleCode="Rrule">6</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Injury, Poisoning and Procedural Complications</td><td styleCode="Rrule">Procedural Pain</td><td styleCode="Rrule">26</td><td styleCode="Rrule">22</td><td styleCode="Rrule">5</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Respiratory, Thoracic and Mediastinal Disorders</td><td styleCode="Rrule">Oropharyngeal Pain</td><td styleCode="Rrule">25</td><td styleCode="Rrule">22</td><td styleCode="Rrule">5</td></tr><tr><td styleCode="Lrule Rrule">Infections and Infestations</td><td styleCode="Rrule">Ear Infection</td><td styleCode="Rrule">30</td><td styleCode="Rrule">21</td><td styleCode="Rrule">5</td></tr></tbody></table>

adverse reactions table

<table width="75%"><caption>Table 4: Postmarketing Experience</caption><col width="50%" align="left" valign="top"/><col width="50%" align="left" valign="top"/><thead><tr><th styleCode="Lrule Rrule" align="center">Organ System [MedDRA Primary SOC]</th><th styleCode="Rrule" align="center">Preferred Term</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Immune System Disorders</td><td styleCode="Rrule">Anaphylactic reaction Hypersensitivity</td></tr><tr><td styleCode="Lrule Rrule">General Disorders and Administration Site Conditions</td><td styleCode="Rrule">Injection site reaction Chills Fatigue/Malaise Chest discomfort/pain Decreased therapeutic effect</td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.